Cargando…
PARK2 promotes mitochondrial pathway of apoptosis and antimicrotubule drugs chemosensitivity via degradation of phospho-BCL-2
Rationale: Neoadjuvant chemotherapy has become the standard treatment of locally advanced breast cancer. Antimicrotubule drugs and DNA-damaging drugs are the most popular medicines used for neoadjuvant chemotherapy. However, we are unable to predict which chemotherapeutic drug will benefit to an ind...
Autores principales: | Chen, Hengxing, Li, Yun, Li, Yu, Chen, Zhen, Xie, Limin, Li, Wenjia, Zhu, Yuanxin, Xue, Hong, Koeffler, H. Phillip, Wu, Wenjing, Hu, Kaishun, Yin, Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481404/ https://www.ncbi.nlm.nih.gov/pubmed/32929329 http://dx.doi.org/10.7150/thno.47044 |
Ejemplares similares
-
RCC2 promotes breast cancer progression through regulation of Wnt signaling and inducing EMT
por: Chen, Zhen, et al.
Publicado: (2019) -
Quick and Simple Detection Technique to Assess the Binding of Antimicrotubule Agents to the Colchicine-Binding Site
por: Fortin, Sébastien, et al.
Publicado: (2010) -
TZT‐1027, an Antimicrotubule Agent, Attacks Tumor Vasculature and Induces Tumor Cell Death
por: Otani, Masashi, et al.
Publicado: (2000) -
Synthesis and Biological Evaluation of Highly Active 7-Anilino Triazolopyrimidines as Potent Antimicrotubule Agents
por: Oliva, Paola, et al.
Publicado: (2022) -
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer
por: Yan, Haiyan, et al.
Publicado: (2016)